Male Contraceptive Gel Shows Promise in Monkeys

Share this content:
Male Contraceptive Gel Shows Promise in Monkeys
Male Contraceptive Gel Shows Promise in Monkeys

WEDNESDAY, Feb. 8, 2017 (HealthDay News) -- A new gel-based vasectomy has proven effective in a group of monkeys, raising hopes it could one day provide a permanent but easily reversible male contraceptive option in humans, according to a study published online Feb. 7 in Basic and Clinical Andrology.

Vasalgel works by plugging the vas deferens, the researchers said. The gel "doesn't break down. It just sets up a little more, and sticks where you inject it," lead researcher Catherine VandeVoort, M.D., a professor of obstetrics and gynecology with the University of California, Davis School of Medicine, told HealthDay.

Sixteen male rhesus macaque monkeys injected with the non-hormonal gel have proven incapable of reproduction, according to the study findings. No females have become pregnant in the males' presence, even though they were housed together for at least one breeding season -- about six months. The team also found few complications, which were similar to those associated with traditional vasectomy.

"Vasalgel placement within the vas deferens seems to be an effective method for contraception in adult male rhesus macaques living in social group settings. Additionally, the presence of Vasalgel appears to be well tolerated and placement resulted in minimal complications," the authors write. "Further study, including the possibility of reversal by flushing the gel from the vasa deferentia in this species, is warranted."

The Parsemus Foundation, based in Berkeley, Calif., holds patents on Vasalgel and funded the study.

Full Text (subscription or payment may be required)

Share this content:

is free, fast, and customized just for you!




Already a member?

Sign In Now »

Trending Activities

All Professions

Drug Lookup

Browse drugs by: BrandGenericDisease

More in Home

FDA Permits Marketing of Brain Stimulation Device for OCD

FDA Permits Marketing of Brain Stimulation Device for ...

FDA previously approved transcranial magnetic stimulation for major depression, certain migraines

Comments Open on End of NIH Review for Gene Therapy Studies

Comments Open on End of NIH Review for ...

NIH oversight panel no longer plans to review all applications for gene therapy experiments

U.S. Measles Outbreak Hits 107 Cases in 21 States, D.C.

U.S. Measles Outbreak Hits 107 Cases in 21 ...

Outbreak on track to exceed last year's; most of the people who got measles weren't vaccinated

is free, fast, and customized just for you!




Already a member?

Sign In Now »